8-K
filed April 5, 2024, 7:59 PM ET
CIK 0001426332
M&A
confidence high
sentiment neutral
materiality 0.90
NGM BIOPHARMACEUTICALS INC: M&A transaction — NGM Bio completes $1.55/share acquisition by Column Group affiliate, goes private
NGM BIOPHARMACEUTICALS INC
- Tender offer closed April 4, 2024; 22,323,295 shares (27% of outstanding) validly tendered at $1.55 each.
- Additional 39,516,567 shares contributed by TCG affiliates under rollover agreements for Parent shares.
- Merger completed April 5, 2024; NGM Bio becomes wholly-owned private subsidiary of Parent.
- Common stock delisted from Nasdaq prior to April 5 trading; deregistration to follow.
- Three independent directors resigned as of Effective Time; CEO David Woodhouse remains as director.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Carole Ho, M.D. resigned as Director at NGM BIOPHARMACEUTICALS INC.
- Action
- resigned
- Role
- Director
Exact text from the filing
immediately following the Effective Time, the directors and officers of the Company immediately prior to the Effective Time became the directors and officers of the Surviving Corporation, except for each of Shelly D. Guyer, Carole Ho, M.D. and Suzanne Sawochka Hooper, who resigned as directors of the Company as of the Effective Time.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Suzanne Sawochka Hooper resigned as Director at NGM BIOPHARMACEUTICALS INC.
- Action
- resigned
- Role
- Director
Exact text from the filing
immediately following the Effective Time, the directors and officers of the Company immediately prior to the Effective Time became the directors and officers of the Surviving Corporation, except for each of Shelly D. Guyer, Carole Ho, M.D. and Suzanne Sawochka Hooper, who resigned as directors of the Company as of the Effective Time.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Shelly D. Guyer resigned as Director at NGM BIOPHARMACEUTICALS INC.
- Action
- resigned
- Role
- Director
Exact text from the filing
immediately following the Effective Time, the directors and officers of the Company immediately prior to the Effective Time became the directors and officers of the Surviving Corporation, except for each of Shelly D. Guyer, Carole Ho, M.D. and Suzanne Sawochka Hooper, who resigned as directors of the Company as of the Effective Time.
View on SEC.gov
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
NGM BIOPHARMACEUTICALS INC: Amended and restated certificate of incorporation (effective 2024-04-05).
- Change
- charter amendment
- Effective
- 2024-04-05
Exact text from the filing
Pursuant to the terms of the Merger Agreement, on April 5, 2024, the Company’s certificate of incorporation and bylaws were amended and restated in their entirety
View on SEC.gov
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
NGM BIOPHARMACEUTICALS INC: Amended and restated bylaws (effective 2024-04-05).
- Change
- bylaw amendment
- Effective
- 2024-04-05
Exact text from the filing
Pursuant to the terms of the Merger Agreement, on April 5, 2024, the Company’s certificate of incorporation and bylaws were amended and restated in their entirety
View on SEC.gov
M&A Transactions
SEC 8-K Item 2.01/5.01
confidence 0.9
NGM BIOPHARMACEUTICALS INC underwent a change of control involving Atlas Neon Parent, Inc. (affiliate of The Column Group, LP) for $1.55 per share in cash (closed 2024-04-05).
- Action
- change of control
- Counterparty
- Atlas Neon Parent, Inc. (affiliate of The Column Group, LP)
- Consideration
- $1.55 per share in cash
- Closing
- 2024-04-05
Exact text from the filing
all of the Company’s outstanding shares of common stock, par value $0.001 per share (the “ Common Stock ”), other than the Rollover Shares (as defined below), in exchange for $1.55 per share of Common Stock in cash (the “ Offer Price ”), subject to and in accordance with the terms and conditions as set forth in the Offer to Purchase, dated March 8, 2024 (as
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
NGM BIOPHARMACEUTICALS INC terminated Sale Agreement with Jefferies LLC (effective 2024-04-05).
- Action
- termination
- Agreement
- atm program
- Counterparty
- Jefferies LLC
- Effective
- 2024-04-05
Exact text from the filing
on April 5, 2024, NGM Biopharmaceuticals, Inc. (the “ Company ” or “ NGM Bio ”) terminated the Open Market Sale Agreement SM , dated as of June 5, 2020 (the “ Sale Agreement ”), as amended by that certain Amendment No. 1 to the Sale Agreement, dated June 7, 2023, by and between the Company and Jefferies LLC.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.